Who
Amir Weiss
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $3.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Feb 2022
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $261K6,945 at $37.61 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | $49K2,500 at $19.61 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $94K2,500 at $37.63 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $48K2,500 at $19.16 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $48K2,500 at $19.16 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $261K6,945 at $37.61 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | $49K2,500 at $19.61 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $94K2,500 at $37.63 | filing |
| 6 May 2026filed 7 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $384K10,679 at $36.00 | filing |
| 6 May 2026filed 7 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $384K10,679 at $36.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —3,537 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,537 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,537 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —3,537 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —10,679 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —5,650 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,679 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,679 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,650 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,280 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Amir Weiss; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.